AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca new Molecular Entities (NMEs) in late-stage pipeline (count)
Clinical Trials Appendix (Pipeline at a glance)
Latest, Q2 2026
21
Period ended Jun 30, 2026
Change on a year earlier
+10.5%
19 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | New Molecular Entities (NMEs) in late-stage pipeline (count) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 21 | +10.5% | Clinical Trials Appendix (2026Q2) ↗ |
| Q1 2026 | Mar 31, 2026 | 21 | +16.7% | Clinical Trials Appendix (2026Q1) ↗ |
| Q4 2025 | Dec 31, 2025 | 20 | +5.3% | Clinical Trials Appendix (2025Q4) ↗ |
| Q3 2025 | Sep 30, 2025 | 20 | -4.8% | Clinical Trials Appendix (2025Q3) ↗ |
| Q2 2025 | Jun 30, 2025 | 19 | -5.0% | Clinical Trials Appendix (2025Q2) ↗ |
| Q1 2025 | Mar 31, 2025 | 18 | -5.3% | Clinical Trials Appendix (2025Q1) ↗ |
| Q4 2024 | Dec 31, 2024 | 19 | +11.8% | Clinical Trials Appendix (2024Q4) ↗ |
| Q3 2024 | Sep 30, 2024 | 21 | – | Clinical Trials Appendix (2024Q3) ↗ |
| Q2 2024 | Jun 30, 2024 | 20 | – | Clinical Trials Appendix (2024Q2) ↗ |
| Q1 2024 | Mar 31, 2024 | 19 | – | Clinical Trials Appendix (2024Q1) ↗ |
| Q4 2023 | Dec 31, 2023 | 17 | – | Clinical Trials Appendix (2023Q4) ↗ |
Cite this data
StockData. (2026). AstraZeneca New Molecular Entities (NMEs) in late-stage pipeline (count), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/cta_late_stage_nmes
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.